<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/156E2C30-184C-4F0F-BC4A-A43C83E8EA86"><gtr:id>156E2C30-184C-4F0F-BC4A-A43C83E8EA86</gtr:id><gtr:firstName>Sam</gtr:firstName><gtr:surname>Alsford</gtr:surname><gtr:orcidId>0000-0001-8621-4920</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK011987%2F1"><gtr:id>E31B3D80-9BC8-4235-AE86-0A8B5B3F81A6</gtr:id><gtr:title>Characterisation of uptake and sub-cellular transit of human serum trypanolytic factors by Trypanosoma brucei</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K011987/1</gtr:grantReference><gtr:abstractText>African trypanosomes are protozoan parasites that cause a range of important human and animal diseases. Human African Trypanosomaiasis (HAT) is typically fatal without drug treatment. Transmission is via the tsetse fly and parasites then circulate in the bloodstream and tissue fluids of their mammalian hosts. The public health situation has improved recently with increased monitoring and therapy averting more than 1.3 million DALYs (Disability-Adjusted Life Years) during 2000 and cases estimated at less than 70,000 in 2006. Humans have an innate immunity to infection by many of the African trypanosomes, mediated by two components of human serum, termed trypanolytic factor (TLF) 1 and 2. The mode of action depends on the ability of apolipoprotein-L1, a component of both trypanolytic factors, to form pores in the lysosome, an organelle responsible for protein degradation. The human infective forms, Trypanosoma brucei gambiense and T. b. rhodesiense, are able to evade this innate immunity by reduced TLF1 uptake or expression of the serum resistance antigen, respectively. There are several outstanding questions: how does TLF2 enter the cell; how do TLF1 and TLF2 transit to the lysosome; which parasite proteins are essential to this process; what are their contributions to TLF efficacy; and, what other routes to human serum resistance exist? Answers to these questions will enable the development of diagnostic tools for the characterisation of wild isolates of African trypanosomes whose human serum sensitivity status is unknown. This is particularly important given the prevalence of African trypanosomes amongst wild and domestic mammals in sub-Saharan Africa and their likely interaction with the human population. The proposal aims to take advantage of recent developments by the applicant, which allow the whole trypanosome genome to be screened for factors that interact with the trypanolytic components of human serum. This approach has already been used to identify the trypanosome factors that interact with and can contribute to resistance to the available anti-HAT drugs. An RNAi library containing fragments corresponding to &amp;gt;99% of the parasite's genes was selected with human serum. Only cells containing RNAi fragments targeting genes whose knockdown reduces sensitivity to human serum survive, and sequencing of these fragments allows the identification of genes and their corresponding proteins that may interact with the trypanolytic components of human serum. An initial analysis identified a surface receptor known to be responsible for the uptake of TLF1 and a lysosomal protein known to influence trypanosome sensitivity to human serum, so validating the approach. Four other proteins were also identified, including one other lysosomal protein, one likely responsible for regulating lysosomal pH, and two other proteins of unknown function. It is now necessary to carry out high throughput sequencing to identify all the genes being targeted by the human serum-selected RNAi library. Characterisation of these genes, their surrounding DNA sequence and their protein products will have several consequences. Firstly, an understanding of the proteins required for trypanolytic factor transit to and action in the lysosome. Secondly, the identification of trypanosome proteins that may contribute to human serum resistance in the field. Thirdly, translation of these findings will lead to the development of tools for the diagnosis and characterisation of wild African trypanosome isolates. This work will present opportunities for the development of diagnostic tools and is also likely to present new opportunities for anti-trypanosomal toxin delivery.</gtr:abstractText><gtr:technicalSummary>African trypanosomes are transmitted by the tsetse fly and circulate in the bloodstream of their host. They cause Human African Trypanosomiasis and nagana in livestock. Humans have an innate immunity to many African trypanosomes, including T. b. brucei, mediated by TLF1/2. The human infective forms, T. b. gambiense and T. b. rhodesiense, evade this by reduced TLF1 uptake and expression of SRA, respectively. Several questions remain: how does TLF2 enter the cell; how does TLF transit the endocytic system; which parasite proteins are essential and what are their roles in TLF efficacy; and, what other routes to TLF resistance exist? Initial sequencing of a T. b. brucei RNAi library selected in normal human serum (NHS) identified the TLF1-receptor and a lysosomal protein, validating the approach. Inhibitor of cysteine peptidase (ICP) and three previously uncharacterised proteins were also identified, including a pH regulator and a transmembrane protein. High throughput sequencing will identify all the RNAi inserts in the selected library. 'Hits' will be subjected to a comparative bioinformatic analysis using the genome sequences: T. b. brucei, T. congolense, T. vivax (sensitive) and T. b. gambiense (resistant). Standard techniques will be used to confirm any variations and to test their role in the T. b. brucei lab-adapted strain. 'Hits' representative of functional categories will be characterised using stemloop RNAi, TLF uptake/ transit assays, epitope-tagging and tandem affinity purification. The role of ICP/cathepsins in TLF efficacy will be analysed by cathepsin stemloop RNAi in an icp null cell line. The pH regulator will be characterised by epitope-tagging, stemloop RNAi, and genetic dissection of the pH regulatory domain. A panel of antibodies will be raised against key proteins identified in these analyses, enabling the translation of the findings into tools for diagnosis and characterisation of African trypanosome isolates of known and unknown NHS sensitivity.</gtr:technicalSummary><gtr:potentialImpactText>The World Health Organization recently stated, &amp;quot;Given the achievements made in the control of sleeping sickness, elimination of the disease as a public health problem can be envisaged. Continuous and strenuous efforts are required to fight the disease and avoid its resurgence as experienced in the 1980s&amp;quot; (WHO Neglected tropical diseases, hidden successes, emerging opportunities). The primary objective of the current proposal is to advance our understanding of the ways in which African trypanosomes can become resistant to lysis by human serum. This will enable the development of tools to analyse the resistance status of field isolates, and will also allow an assessment of the likelihood of previously non-infectious sub-species developing resistance, and therefore becoming infectious to humans. This could be particularly important given the recent successes regarding the control of human African trypanosomiasis in an environment where non-human infective trypanosomes are still highly prevalent. Thus, the populations vulnerable to this devastating disease, as well as the researchers, health systems and related organizations in endemic countries will benefit from this research.

The research will provide new knowledge and scientific advancement, and addresses a key issue of importance to Africa. It will also deliver training to a highly skilled researcher. Although commercial exploitation is not a major driving force underlying most neglected tropical disease research, this particular proposal does have the potential to generate commercially exploitable results.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-08-18</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>366190</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A391A789-3355-4DBC-B559-8AD85D44FCEB</gtr:id><gtr:title>Subverting lysosomal function in.</gtr:title><gtr:parentPublicationTitle>Microbial cell (Graz, Austria)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c36b617b7e071e244219d3e41650e49"><gtr:id>2c36b617b7e071e244219d3e41650e49</gtr:id><gtr:otherNames>Alsford S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2311-2638</gtr:issn><gtr:outcomeId>55f817a97b79a8.05130342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B89D8FB-65C0-4438-B5F3-3C3345E5E03E</gtr:id><gtr:title>Ornithine uptake and the modulation of drug sensitivity in.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a7602670e42f41da779b4938bdd7766"><gtr:id>3a7602670e42f41da779b4938bdd7766</gtr:id><gtr:otherNames>Macedo JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>5a0eef05d9a974.59992467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99EAEFE9-D039-4EB0-8165-30AC585DE4A5</gtr:id><gtr:title>Decoding the network of Trypanosoma brucei proteins that determines sensitivity to apolipoprotein-L1.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4ada6e8a3e374a9df8c109190256ed5"><gtr:id>b4ada6e8a3e374a9df8c109190256ed5</gtr:id><gtr:otherNames>Currier RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5a633bf96a7c20.80915035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>963548C0-ADE2-445A-B8D8-75C048206889</gtr:id><gtr:title>Genetic dissection of drug resistance in trypanosomes.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c36b617b7e071e244219d3e41650e49"><gtr:id>2c36b617b7e071e244219d3e41650e49</gtr:id><gtr:otherNames>Alsford S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn><gtr:outcomeId>pm_540e197e19753a492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7FD66C0-625D-42E2-9250-B86F5ECED530</gtr:id><gtr:title>Cathepsin-L can resist lysis by human serum in Trypanosoma brucei brucei.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c36b617b7e071e244219d3e41650e49"><gtr:id>2c36b617b7e071e244219d3e41650e49</gtr:id><gtr:otherNames>Alsford S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_23046_26_24830321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B130D9F-B65B-42BF-933C-F96F2288AAB3</gtr:id><gtr:title>Increasedcathepsin-L activity inhibits human serum-mediated trypanolysis.</gtr:title><gtr:parentPublicationTitle>Microbial cell (Graz, Austria)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c36b617b7e071e244219d3e41650e49"><gtr:id>2c36b617b7e071e244219d3e41650e49</gtr:id><gtr:otherNames>Alsford S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2311-2638</gtr:issn><gtr:outcomeId>5449683a0efdc3.26330196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4499885E-9C0C-4137-A3A4-6E8F4ED20B88</gtr:id><gtr:title>Genome-scale RNAi screens for high-throughput phenotyping in bloodstream-form African trypanosomes.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71ceeea282e6bb69617bf0962dda6c6b"><gtr:id>71ceeea282e6bb69617bf0962dda6c6b</gtr:id><gtr:otherNames>Glover L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>563a2f9ac7fcd8.16059456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EA7F078-A85D-4295-A95B-E575EA8138E4</gtr:id><gtr:title>Receptor-mediated endocytosis for drug delivery in African trypanosomes: fulfilling Paul Ehrlich's vision of chemotherapy.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c36b617b7e071e244219d3e41650e49"><gtr:id>2c36b617b7e071e244219d3e41650e49</gtr:id><gtr:otherNames>Alsford S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>585d5a64bda936.93908833</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K011987/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>